Katrine F. Iversen
Vejle, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort.
Journal: American journal of hematology
Published: March 09, 2026
Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma.
Journal: Journal of extracellular vesicles
Published: May 26, 2025
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.
Journal: EJHaem
Published: June 06, 2024
Mechanisms of resistance to daratumumab in patients with multiple myeloma.
Journal: Basic & clinical pharmacology & toxicology
Published: January 03, 2024
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens.
Journal: Clinical hematology international
Published: February 25, 2022
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy.
Journal: American journal of hematology
Published: September 10, 2021
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
Journal: Hematological oncology
Published: June 11, 2021
The real-world outcomes of multiple myeloma patients treated with daratumumab.
Journal: PloS one
Published: March 19, 2021
The Incidence and Timing of Blood Cultures in Multiple Myeloma - Results from a Retrospective, Single Center, Real-World Study.
Journal: Clinical hematology international
Published: May 14, 2020
Last Updated: 09/26/2026